secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2026-05-14T20:18:53+00:00
Accession:  0001477932-26-003126
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test
--------------------------------------------------------------------------------

- Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.
- Net cash used in operations was $5.3M; raised $5.4M from ATM equity and $1.9M from convertible note.
- Received $1M in non-dilutive Walloon Region funding; ~$0.9M more expected over 12 months.
- Feline lymphoma assay manuscript submitted for peer review; expected to unlock $5M milestone payment.
- Discussions ongoing with >12 diagnostic companies for licensing; Nu.Q Lung Cancer reimbursement in France progressing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793226003126/0001477932-26-003126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793226003126/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-003126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer